San Diego, CA, US - Inova Diagnostics, a worldwide leader in autoimmune diagnostic reagents and systems for the clinical laboratory, is pleased to announce the launch of QUANTA Flash® Calprotectin, an assay which aids in the diagnosis of Inflammatory Bowel Disease (IBD), and can help differentiate IBD from Irritable Bowel Syndrome (IBS).  The assay is now available in territories where diagnostic products with CE mark may be marketed.  QUANTA Flash Calprotectin is one of 32 CE marked assays available on BIO-FLASH®, a random access chemiluminescent instrument, and can be run simultaneously with other QUANTA Flash assays.  

The accurate detection of calprotectin levels can provide critical information to physicians determining the appropriate care of millions of patients suffering from gastrointestinal disorders.  QUANTA Flash Calprotectin is a chemiluminescent immunoassay for the quantitative determination of fecal calprotectin in extracted human stool samples.      

QUANTA Flash Calprotectin delivers precise quantification, with an analytical measuring range of up to 3,500 mg/kg, and can provide insight where follow up testing is performed.  According to Michael Mahler, PhD, Vice President of Research and Development for Inova Diagnostics, "We are very pleased to launch this high performing assay to meet the increasing demand from laboratories worldwide.  Gastrointestinal pain is a common reason for seeking medical attention. Inaccurate results at the screening level can contribute to unnecessary procedures and increased healthcare costs. QUANTA Flash Calprotectin, with its broad dynamic range and high accuracy, can improve care while helping reduce costs.”